T cell primary proliferative response to antigens and mitogen in patients with multiple sclerosis: Assessment of an immunosuppressive treatment with mitoxantrone

G. Ristori, M. Salvetti, M. Falcone, P. Fiori, C. Buttinelli, E. Millefiorini, C. Pozzilli

Research output: Contribution to journalArticle

Abstract

To investigate the use of T cell reactivity in evaluating the effect of immunosuppressive treatments in Multiple Sclerosis (MS), we studied the T cell primary proliferative response to myelin basic protein, PPD and phytohemagglutinin in 6 relapsing-remitting patients, included in a placebo-controlled trial of mitoxantrone (MX). Blood collection, clinical evaluation and Gd-enhanced MRI were performed (on the same day) before and after two months of treatment. No decrease of antigen and mitogen stimulation indexes after therapy was observed in both MX and placebo treated patients. Accordingly, no difference between the two groups was evident comparing leucocyte counts before and after therapy. The negative result may be due to the posology of drug employed in the clinical trial. The use of T cell primary response to antigens, including putative autoantigens, and mitogen, may represent a functional approach to the assessment of immunosuppressant and immunomodulatory drugs in MS patients.

Original languageEnglish
Pages (from-to)137-138
Number of pages2
JournalEOS Rivista di Immunologia ed Immunofarmacologia
Volume14
Issue number3-4
Publication statusPublished - 1994

Fingerprint

Mitoxantrone
Immunosuppressive Agents
Mitogens
Multiple Sclerosis
T-Lymphocytes
Antigens
Placebos
Myelin Basic Protein
Tuberculin
Autoantigens
Phytohemagglutinins
Therapeutics
Leukocyte Count
Pharmaceutical Preparations
Clinical Trials

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

T cell primary proliferative response to antigens and mitogen in patients with multiple sclerosis : Assessment of an immunosuppressive treatment with mitoxantrone. / Ristori, G.; Salvetti, M.; Falcone, M.; Fiori, P.; Buttinelli, C.; Millefiorini, E.; Pozzilli, C.

In: EOS Rivista di Immunologia ed Immunofarmacologia, Vol. 14, No. 3-4, 1994, p. 137-138.

Research output: Contribution to journalArticle

@article{756193b972444adbb3a450d4824234bc,
title = "T cell primary proliferative response to antigens and mitogen in patients with multiple sclerosis: Assessment of an immunosuppressive treatment with mitoxantrone",
abstract = "To investigate the use of T cell reactivity in evaluating the effect of immunosuppressive treatments in Multiple Sclerosis (MS), we studied the T cell primary proliferative response to myelin basic protein, PPD and phytohemagglutinin in 6 relapsing-remitting patients, included in a placebo-controlled trial of mitoxantrone (MX). Blood collection, clinical evaluation and Gd-enhanced MRI were performed (on the same day) before and after two months of treatment. No decrease of antigen and mitogen stimulation indexes after therapy was observed in both MX and placebo treated patients. Accordingly, no difference between the two groups was evident comparing leucocyte counts before and after therapy. The negative result may be due to the posology of drug employed in the clinical trial. The use of T cell primary response to antigens, including putative autoantigens, and mitogen, may represent a functional approach to the assessment of immunosuppressant and immunomodulatory drugs in MS patients.",
author = "G. Ristori and M. Salvetti and M. Falcone and P. Fiori and C. Buttinelli and E. Millefiorini and C. Pozzilli",
year = "1994",
language = "English",
volume = "14",
pages = "137--138",
journal = "EOS Rivista di Immunologia ed Immunofarmacologia",
issn = "0392-6699",
publisher = "Sigma-Tau SpA",
number = "3-4",

}

TY - JOUR

T1 - T cell primary proliferative response to antigens and mitogen in patients with multiple sclerosis

T2 - Assessment of an immunosuppressive treatment with mitoxantrone

AU - Ristori, G.

AU - Salvetti, M.

AU - Falcone, M.

AU - Fiori, P.

AU - Buttinelli, C.

AU - Millefiorini, E.

AU - Pozzilli, C.

PY - 1994

Y1 - 1994

N2 - To investigate the use of T cell reactivity in evaluating the effect of immunosuppressive treatments in Multiple Sclerosis (MS), we studied the T cell primary proliferative response to myelin basic protein, PPD and phytohemagglutinin in 6 relapsing-remitting patients, included in a placebo-controlled trial of mitoxantrone (MX). Blood collection, clinical evaluation and Gd-enhanced MRI were performed (on the same day) before and after two months of treatment. No decrease of antigen and mitogen stimulation indexes after therapy was observed in both MX and placebo treated patients. Accordingly, no difference between the two groups was evident comparing leucocyte counts before and after therapy. The negative result may be due to the posology of drug employed in the clinical trial. The use of T cell primary response to antigens, including putative autoantigens, and mitogen, may represent a functional approach to the assessment of immunosuppressant and immunomodulatory drugs in MS patients.

AB - To investigate the use of T cell reactivity in evaluating the effect of immunosuppressive treatments in Multiple Sclerosis (MS), we studied the T cell primary proliferative response to myelin basic protein, PPD and phytohemagglutinin in 6 relapsing-remitting patients, included in a placebo-controlled trial of mitoxantrone (MX). Blood collection, clinical evaluation and Gd-enhanced MRI were performed (on the same day) before and after two months of treatment. No decrease of antigen and mitogen stimulation indexes after therapy was observed in both MX and placebo treated patients. Accordingly, no difference between the two groups was evident comparing leucocyte counts before and after therapy. The negative result may be due to the posology of drug employed in the clinical trial. The use of T cell primary response to antigens, including putative autoantigens, and mitogen, may represent a functional approach to the assessment of immunosuppressant and immunomodulatory drugs in MS patients.

UR - http://www.scopus.com/inward/record.url?scp=0028609521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028609521&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028609521

VL - 14

SP - 137

EP - 138

JO - EOS Rivista di Immunologia ed Immunofarmacologia

JF - EOS Rivista di Immunologia ed Immunofarmacologia

SN - 0392-6699

IS - 3-4

ER -